Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. (2022)

First Author: Turkova A

Attributed to: Blood borne viruses funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2352-3018(22)00160-6

PubMed Identifier: 35868341

Publication URI: http://europepmc.org/abstract/MED/35868341

Type: Journal Article/Review

Volume: 9

Parent Publication: The lancet. HIV

Issue: 9

ISSN: 2352-3018